Brett charles plyler

Brett Charles Plyler, M.D.

Employment

2008-Present
Northwestern Memorial Hospital.
Instructor for second year residents’ psychotherapy class and individual resident supervision. Chicago IL. Chicago Research Center, Inc.
Private Practice.
Outpatient/Inpatient and psychotherapy/psychopharmacology. Chicago IL. Northwestern Memorial Hospital.
Attending psychiatrist for inpatients. Chicago IL. Cook County Jail.
Staff psychiatrist for inpatients. Chicago, IL. Family Alliance.
Outpatient geriatric treatment. Woodstock, IL. Oak Forest Psychological Services.
Conducted group psychotherapy. Chicago, IL. Lakeshore Mental Health Institute.
Staff physician responsible for medical and psychiatric problems of inpatient Jellico Community Hospital.
East Tennessee Medical Group.
Staff physician for an urgent care clinic. Maryville, TN. Peninsula Psychiatric Hospital.
Staff physician responsible for involuntary commitments. Knoxville, TN.
Education

2006
Board Certification Adult General Psychiatry.

2004- Present
Adult Psychodynamic Psychotherapy Program.
Institute for Psychoanalysis. Chicago IL. Rush St. Luke’s Presbyterian Medical Center.
General Psychiatry Residency program. Chicago IL.
Education

2003-2004
Rush St. Luke’s Presbyterian Medical Center.
Chief Resident of General Psychiatry program. 2002 Board Certification Family Practice.
University of Tennessee Medical Center at Knoxville.
University of Tennessee, Memphis, School of Medicine.
University of Tennessee, Knoxville.
B.A., College Scholars (Psychology and History).
Research

A Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled Study Followed By a 6-Month
Open-Label Extension To Evaluate The Efficacy and Safety of DVS SR in Peri – and Postmenopausal
Women With Major Depressive Disorder, Protocol# 315A1-403-WW, Wyeth, 2006 Principal Investigator
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and
Safety of Sustained-release Quetiapine Fumarate (SEROQUEL®) Compared with Placebo in the Treatment
of Generalized Anxiety Disorder, Protocol# D1448C00009, AstraZeneca, 2006 Principal Investigator

A Randomized, Double-Blind, Placebo Controlled Study of the Efficacy of PRX-0023 in Patients With
Major Depressive Disorder, Protocol# EPX-CP-020, Epix, 2007 Principal Investigator
A Multicenter, Multiple Dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of
the Safety and Efficacy of AGN 203818 in Female Patients With Fibromyalgia Syndrome, Protocol#
203818-503-00, Allergan 2007 Principal Investigator
A Multicenter, Randomized, Double-blind, Parallel-group, Placebocontrolled Study of the Efficacy and
Safety of Quetiapine Fumarate Extended-Release (SEROQUEL® XR) Compared with Placebo as an
Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No
Response to a Selective Serotonin Reuptake Inhibitor or Serotonin-Norepinephrine Reuptake Inhibitor
Alone or in Combination with a Benzodiazepine, Protocol# D1441L00016, Astra Zeneca 2007 Principal
Investigator
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy
and Safety of VEC-162 (20mg/day and 50 mg/day) in the Treatment of Primary Insomnia, Protocol# VP-
VEC-162-3104, Vanda 2007 Sub Investigator
A Phase III Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy
and Safety of MK-0431A in Patients with Type 2 Diabetes Mellitus, Protocol# 097-00, Merck 2007 Sub
Investigator
A double-blind, randomized, parallel group, placebo-controlled sleep laboratory efficacy and safety study
with Org 50081 in elderly subjects with chronic primary insomnia, Protocol# 21108, Organon 2007 Sub
Investigator


Research
Efficacy and safety of 2 mg/day M100907 on Sleep Maintenance Insomnia: a 6-week, multicenter,
randomized, double-blind, placebo-controlled Polysomnographic study, Protocol# EFC6072, Sanofi-
Aventis 2007 Sub Investigator
A six-week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep
Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia, Protocol# 176002, Organon, 2007
Sub Investigator

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of MAP0004 in Adult
Migraineurs for a Single Migraine Followed by Open -Label Extensions to 26/52 Weeks, Protocol #
MAP0004-CL P301, Map 2007 Sub Investigator
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients with Major
Depressive Disorder, Protocol# CLDA-07-DP-04, PGXHealth 2007 Principal Investigator
Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment
of Breakthrough Cancer Pain, Protocol# INS-06-007, Insys Therapeutics 2007 Sub Investigator

A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and
Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential
Hypertension, Protocol# 01-06-TL-491-019, Takeda 2008 Sub Investigator
A Randomized, Double-blind, Placebo-controlled Subjective Study to Assess the Efficacy of APD125 in
Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep, Protocol# APD125-007,
Arena 2008 Sub Investigator
Efficacy and Safety of Eplivanserin 5mg/day in Insomnia Characterized by Sleep Maintenance Difficulties:
a 6-week, Randomized, Double-Blind, Placebo-Controlled, Polysomnography Study, Protocol#
EFC10844/ECLIPSE, Sanofi-Aventis 2008 Sub Investigator

A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover
Polysomnography Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary
Insomnia, Protocol# MK-4305 006-00, Merck 2008 Sub Investigator

A Multicenter, Multiple Dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of
the Safety and Efficacy of AGN 230818 in Female Patients with Fibromyalgia Syndrome Protocol
#203818-503-01, Allergan 2008 Principal Investigator
A 6-Month Placebo-Controlled Study Of Pagoclone 0.075 MG, 0.30 MG OR 0.60 MG Twice Daily In
Adults With Stuttering, #IP456-041, Indevus 2009 Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and
Safety of Armodafinil at a Target Dosage of 200 mg/day as Treatment for Adults With Excessive
Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Comorbid Major
Depressive Disorder or Dysthymic Disorder, Protocol # C10953/4024/ES/US, Cephalon 2008 Sub
Investigator
Effects of Pregabalin on Sleep Maintenance in Subjects With Fibromyalgia Syndrome nad Sleep
Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study,
Protocol# A0081165, Pfizer 2009 Principal Investigator

A Randomized, Placebo-Controlled, Double-Blind, Fixed –Dose Study of the Efficacy and Safety of
Eszopiclone in Children (6 to 11 years) and Adolescents (12 to 17 years) with Attention-
Deficit/Hyperactivity Disorder-Associated Insomnia, Protocol# 190-246, Sepracor 2009 Principal
Investigator


Research

A Long-Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 years) and Adolescents (12
to 17 years) with Attention-Deficit/Hyperactivity Disorder-Associated Insomnia, Protocol# 190-247,
Sepracor 2009 Principal Investigator

A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive
Disorder, Protocol# LVM-MD-02, Forest 2009 Principal Investigator
A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive
Disorder. Protocol# LVM-MD-04, Forest 2009 Principal Investigator

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term
Safety Study of MK-4305 in Patients with Primary Insomnia. Protocol#MK4305-009, Merck 2009 Sub-
Investigator
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and
Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms
Associated with Menopause. Protocol#N30-003, Noven Therapeutics 2010 Sub Investigator
A 12-week, Randomized, Double-Blind, Placebo-Controlled, Phase III Safety Trial of Flibanserin Tablets
(100 milligrams daily) in Women Taking a Selective Serotonin or Serotonin-Norepinephrine Reuptake
Inhibitor With Decreased Sexual Desire and Distress, Protocol#511.114, Boehringer-Ingelheim 2009
Principal Investigator
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse-Prevention study With F2695 SR in
Patients With Major Depressive Disorder. Protocol# LVM-MD-05, Forest 2010 Principal Investigator
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and
Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in
Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy.
Protocol# D4130C00002 (Flex), AstraZeneca 2010 Principal Investigator
A Multicenter, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase III, Long-Term Safety
and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with
Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy. Protocol#
D4130C00007 (LTSS), AstraZeneca 2010 Principal Investigator
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group,
Polysomnography Study to Evaluate the Safety and Efficacy of MK-4305 in Elderly Patients with Primary
Insomnia. Protocol# MK4305-0029, Merck 2010 Sub-Investigator
A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography study
Of Pregabalin and Pramipexole in Adults With Restless Legs Syndrome. Protocol# A008118, Pfizer 2010
Sub-Investigator
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of
Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving
Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With
Shift Work Disorder. Protocol# C10953/4030, Cephalon 2010 Sub-Investigator


Honors and Awards

1993 Phi Beta Kappa.
1990 Phi Kappa Phi Honor Society.

1990-1994 College Scholars Program. University of Tennessee, Knoxville.
merit-based individualized undergraduate program of study.
1989-1993 National Merit Scholarship.
1989-1993
Robert S. Wood Trustee Scholarship. University of Tennessee, Knoxville, tuition
merit scholarship.

Extracurricular
2003-Present Book Reviewer, Doody’s Book Review Service.
Reviewed current texts on mental health prior to general publication. Camp Physician, Boy Scouts of America, Camp Buck Toms.
Responsible for healthcare of scouts and staff during summer camp.
American Association of Family Physicians.

1994-Present
American Medical Association.

1996-1998
Family Practice Student Association.

Source: http://www.chicagopsychiatryassociates.org/cvs/Brett_Plyler_CV.pdf